The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year

2020

Stage

Secondary Market | Alive

Total Raised

$7.3M

About AffyXell Therapeutics

AffyXell Therapeutics was developed by Avacta and Daewoong as a Joint Venture to develop novel mesenchymal stem cell (MSC) therapies.

AffyXell Therapeutics Headquarter Location

England,

United Kingdom

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing AffyXell Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

AffyXell Therapeutics is included in 1 Expert Collection, including Regenerative Medicine.

R

Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

Latest AffyXell Therapeutics News

  • When was AffyXell Therapeutics founded?

    AffyXell Therapeutics was founded in 2020.

  • What is AffyXell Therapeutics's latest funding round?

    AffyXell Therapeutics's latest funding round is Secondary Market.

  • How much did AffyXell Therapeutics raise?

    AffyXell Therapeutics raised a total of $7.3M.

  • Who are the investors of AffyXell Therapeutics?

    Investors of AffyXell Therapeutics include Avacta, Shinhan Venture Investment, Shinhan Investment Corp., KOLON INVESTMENT, Gyeongnam Venture Investment and 6 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.